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Aminotransferase as a Prognostic Index in Infants with Liver Disease

Philip Rosenthal' and Michael Haight
To assess the utility of the serum aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio in a group of infants with liver disorders, we retrospectively analyzed the charts of 73 infants with chronic liver disorders. Patients were considered as having either a good outcome (n = 40) or a poor outcome (n = 33), based upon the clinical course. AST and ALT in serum were measured simultaneously at the time of initial presentation and at various follow-up visits during the first 13 months after birth. At presentation (mean age 1.65 months), there was no difference in the AST/ALT ratios between the good (1.61 ± 0.62; mean ± SD) and poor (1.65 ± 0.78) outcome groups (P = 0.81). However, over time, the AST/ALT ratio increased in patients in the poor-outcome group and decreased in patients in the good-outcome group. Calculating the AST/ALT ratio appears to be an easy, early, and reliable prognostic indicator for infants with hepatic disease, and may be a useful measure for evaluating liverdisease patients.
Advances in the diagnosis and treatment of pediatric liver disorders have markedly improved survival rates for children with liver disease (1).Unfortunately, a substantial number of children continue to die from complications of their primary hepatic pathology while awaiting liver transplantation.
Given the limited number of donor organs, identification of the infants at greatest risk who might benefit from earlier hepatic transplantation could be of considerable utility.
The ratio between aspartate aminotransferase (AST, EC 2.6.1.1) and alanine aminotransferase (ALT, EC 2.6.1.2),
AST/ALT, has been found to be a useful indicator of hepatic disease in adults (2).In adult patients with nonalcoholic liver disease, an AST/ALT ratio increasing to >1.0 suggests cirrhosis, whereas a ratio <1.0 is usually seen in patients with chronic hepatitis, survivors of acute viral hepatitis, and patients with chronic cholestatic syndromes In an attempt to identify an easily measured and reliable index that would assist in the early evaluation of infants with liver disorders and offer a prognostic guide to their outcome, we assessed the utility of the AST/ALT ratio in the serum of a group of such infants.
Patients and Methods
We retrospectively analyzed the charts of 73 infants with chronic liver disorders, who had been referred to our (CMV) hepatitis, 11 with idiopathic neonatal hepatitis, six with alpha-1-antitrypsin deficiency liver disease, and two with arteriohepatic dysplasia (Alagille's syndrome). There were 39 boys and 34 girls.
Patients were assigned to either a good-outcome (n = 40) or poor-outcome (n = 33) group, based on their clinical course. Poor outcome was defined as evidence of cirrhosis, portal hypertension, esophageal varices, ascites, liver transplantation, or death. Patients in the good-outcome group had no signs of chronic liver disease or any of the findings used to define a poor outcome. Follow-up assessments were made from three months to 10 years later (mean 23 months).
AST and ALT activity concentrations were measured simultaneously in serum of each patient at the time of initial presentation and at various intervals at follow-up visits with an automated procedure (Abbott Bichromatic Analyzer, ABA-100; Abbott Labs., Abbott Park, IL) in our clinical chemistry laboratory under standard laboratory conditions (7) . The serum AST/ALT ratios during the first 13 postnatal months were calculated from these serial values. We used Student's t-test At the time of initial presentation (ages one week to five months, mean 1.65 months), there was no significant difference in mean AST/ALT ratios between the good-outcome (1.61, SD 0.62) and poor-outcome (1.65, SD 0.78) groups (P = 0.81). However, if the AST/ALT ratios were followed serially over time, the ratio increased in patients in the poor-outcome group and decreased in patients in the goodoutcome group (Table 1) . Given the range of AST/ALT ratios, a single determination of the AST/ALT ratio during the first year of infancy was not predictive of outcome. By ages five to seven months, however, infants in the goodoutcome group already tended to have an AST/ALT ratio <1.50 while infants in the poor-outcome group tended to have an AST/ALT ratio 1.50 (Figure 1 ).
Discussion
The present study demonstrates the utility of calculating and following serially the serum AST/ALT ratio in infants with liver disease. Through retrospective analysis, we were able to examine the AST/ALT ratios in patients in whom diagnosis and outcome were established. This way, we could exclude patients with myocardial injury, circulatory congestion, muscle injury, central nervous system disease, immediate postoperative states, and other nonhepatic conditions accompanied by increased serum aminotransferases
(transaminases).
AST and ALT catalyze the transfer of the alpha-amino groups of aspartate and alanine, respectively, to the alphaketo group of ketoglutaric acid, resulting in the formation of oxaloacetic acid and pyruvic acid. Whereas AST is present in a wide variety of tissues (heart, skeletal muscle, kidney, and brain) in addition to liver, ALT is primarily found only in the liver (3).AST in the liver is present in both mitochondria and cytosol, with 80% of hepatic AST activity residing in the mitochondria (8) . ALT in the liver is limited to the cytosol (3).
The AST/ALT ratio in the cytoplasm of the hepatocyte is 0.6, whereas the AST/ALT ratio in the total hepatocyte (including cytoplasm and mitochondria) is 3.0 (9). The isoenyzmes of AST differ in cytoplasm and mitochrondria
(8).
Values for serum AST and ALT were abnormally high in all the infants at presentation. Although this may reflect the extent of hepatocyte necrosis, the increases do not correlate with outcome. Although declining values for serum AST and ALT may indicate recovery, they may also indicate a poor prognosis if there is a paucity of remaining hepatocytes to contribute to the serum enzyme pools. In most of these infants, serum AST and ALT were either slightly or moderately increased. In general, the AST/ALT ratio was lower for infants in the good-outcome group compared with the poor-outcome group. This may be the result of the extent of hepatic injury and localization of transaminases within the hepatocyte. ALT is exclusively localized in the cytoplasm of the hepatocyte. In mild hepatic injury, only the hepatocyte membrane is damaged, releasing only cytoplasmic enzymes (including AST and ALT) but leaving hepatic mitochrondrial membranes intact. Because the AST/ALT ratio in the hepatic cytoplasm is 0.6, a low AST/ALT ratio in serum is to be expected. However, with more severe hepatic injury, both hepatocyte cytoplasmic and mitochondrial membranes are damaged with pooling of enzymes from both sources. Because total hepatocyte AST/ALT is Age, months 3.0, more severe damage results in a higher serum AST/ ALT ratio.
In the present study, we used values for total AST and ALT in serum. These are more easily and more routinely measured than the isoenzymes of AST. Although patients with obvious nonhepatic conditions that cause increased serum transaminases were excluded, the contribution to AST from nonhepatic sources or artifactual changes caused by hemolysis could not be excluded. Further, the formation, metabolism, or elimination of AST and ALT in this retrospective review could not be evaluated.
The AST/ALT ratio appears to be an easy, early, and reliable prognostic indicator for infants with hepatic disease. A prospective study appears warranted to determine the benefits this screening test may have in allocations of resources and planning for infants with hepatic disease who may subsequently require hepatic transplantation.
This simple and readily obtainable calculation may prove to be a useful measure for evaluating liver-disease patients.
